Volume 21, Number 3—March 2015
Research
Risk Factors for Death from Invasive Pneumococcal Disease, Europe, 2010
Adoración Navarro-Torné
, Joana Gomes Dias, Frantiska Hruba, Pier Luigi Lopalco, Lucia Pastore-Celentano, Andrew J. Amato Gauci, and Invasive Pneumococcal Disease Study Group
, Joana Gomes Dias, Frantiska Hruba, Pier Luigi Lopalco, Lucia Pastore-Celentano, Andrew J. Amato Gauci, and Invasive Pneumococcal Disease Study Group
Table 4
Association between invasive pneumococcal disease study variables and death, Europe, 2010*
| Variable | Relative risk† (95% CI) |
|---|---|
| Sex | |
| F | Reference |
| M | 1.06 (0.88–1.28) |
| Age group, y | |
| <5 | Reference |
| 5–64 | 3.55 (1.66–7.61) |
| >65 | 4.79 (3.08–11.76) |
| Clinical presentation | |
| Nonmeningitis | Reference |
| Meningitis | 1.81 (1.25–2.61) |
| Serotype | |
| PCV13-specific‡ | Reference |
| PCV7 | 2.18 (1.06–4.48) |
| Non-PCV | 1.47 (0.94–2.28) |
| Antimicrobial susceptibility | |
| Penicillin | |
| Susceptible | Reference |
| Nonsusceptible§ | 1.91 (1.16–3.13) |
| Erythromycin | |
| Susceptible | Reference |
| Nonsusceptible | 1.04 (0.84–1.29) |
*PCV, pneumococcal conjugate vaccine; PCV7, 7-valent PCV; PCV13, 13-valent PCV..
†Generalized linear model with log-link function.
‡Serotypes contained in PCV13 but not in PCV7.
§Either resistant or intermediate resistance.
1Members of the Invasive Pneumococcal Disease Study Group who contributed data are listed at the end of this article.
Page created: April 16, 2015
Page updated: April 16, 2015
Page reviewed: April 16, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.